linjc16/ctgov huggingface dataset:
Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger

Study Overview
=================
Brief Summary
-----------------
Omitting the GnRH antagonist on the day of the trigger can be cost effective and more convenient to the women. We will study the impact of omitting the antagonist dose in a prospective randomized trial

Official Title
-----------------
Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles

Conditions
-----------------
Pituitary Downregulation

Intervention / Treatment
-----------------
* Drug: Omit Citrotide 0.25 dose on the day of triggering of ovulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All antagonist cycle ivf who agree to participate Exclusion Criteria: expected poor responders.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled study
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: -ve arm<br>The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm) | Drug: Omit Citrotide 0.25 dose on the day of triggering of ovulation<br>* Omit Citrotide 0.25 dose on the day of triggering of ovulation<br>|
| No Intervention: +ve arm<br>The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of retrieved oocytes | total number and maturation of the retrieved oocytes | One Month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GnRH antagonist, Pituitary downregulation, IVF, ICSI
Correlation Between Access Blood Flow and Extracorporeal Blood Flow

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if Effective Extracorporeal Blood Flow(eEBF) has correlation with Access Blood Flow (Qa), when eEBF adjusts with Dynamic Arterial Line Pressure (DALP) in patients with Arteriovenous fistulae in hemodialysis treatment.

Detailed Description
-----------------
Accesses that show a large (>15%) decrement over time in vascular access blood flow are associated with a high risk of thrombosis. Serial measurements of vascular access blood flow predict access thrombosis. At the moment, the measurement of access flow is time consuming, operator dependent, so that it cannot be done with every treatment. We hypothesized that extracorporeal blood flow at pressure of -200 to -260 mmHg in arterial line has correlation with access blood flow and this can be used to estimate access blood flow.

Official Title
-----------------
Correlation Between Access Blood Flow and Extracorporeal Blood Flow

Conditions
-----------------
Arteriovenous Fistula

Intervention / Treatment
-----------------
* Other: Dynamic Arterial line Pressure (DALP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Chronic Kidney Disease K-DIGO 5d in hemodialysis treatment) Permanent vascular accesses with native arteriovenous fistulas (AVF) AVF that were at least 12 weeks old Exclusion Criteria: Inflammation and pain in AVF Negation to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acces Blood Flow | Acces Blood Flow: cuantity of Blood that Flow throw venous acces in ml/min | Acces Blood Flow | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arteriovenous fistula, Access blood flow, Extracorporeal blood flow, Dynamic arterial line pressure, Hemodialysis treatment
Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was the bioequivalence of a Roxane Laboratories' Amlodipine Besylate tablets, 10 mg, to Norvasc® Tablets, 10 mg (Pfizer) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.

Official Title
-----------------
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fed Conditions

Conditions
-----------------
Hypertension, Chronic Stable Angina, Vasospastic Angina

Intervention / Treatment
-----------------
* Drug: Amlodipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Amlodipine Besylate or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Amlodipine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence |  | Baseline, Two period, Twenty-one day washout |
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

Study Overview
=================
Brief Summary
-----------------
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Official Title
-----------------
Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Conditions
-----------------
Polypoidal Choroidal Vasculopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Polypoidal choroidal vasculopathy must have injection of Ranibizumab Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab |  | a month after injection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Polypoidal Choroidal Vasculopathy, Ranibizumab
Airway Management and Weight in Children

Study Overview
=================
Brief Summary
-----------------
The investigators in this study want to see how overweight/obese children who undergo elective surgery requiring airway management react to general anesthesia. They believe that the incidence of perioperative respiratory adverse events (PRAE) associated with Laryngeal mask airway (LMA) use during general anesthesia in overweight/obese children is lower than that associated with endotracheal intubation (ETT).

Official Title
-----------------
Laryngeal Mask Airway Versus Endotracheal Intubation for Airway Management During General Anesthesia in Obese Children

Conditions
-----------------
Perioperative Respiratory Adverse Events, Airway Management

Intervention / Treatment
-----------------
* Device: Endotracheal intubation
* Device: Laryngeal mask airway


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sex-specific body mass index (BMI) is ≥85th percentile elective surgical outpatient peripheral or lower abdominal procedures Surgery length estimated to last between 30 and 120 minutes Exclusion Criteria: Active gastro-esophageal reflux, possible difficult intubation or planned asleep fiber optic intubation, cardiac disease, thoracic deformities, upper abdominal, and thoracic or airway surgeries. Children with active asthmatic attack or those considered to be full stomach will also be excluded. Laparoscopic surgical procedures and those requiring extreme head-down tilt will also be excluded. Children with a physiology or other condition requiring a certain type of airway for the procedure will also be excluded Children whose anesthesiologist is not agreeable to randomization of airway management choice will also be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endotracheal intubation<br> | Device: Endotracheal intubation<br>* COMPLETE<br>|
| Experimental: Laryngeal mask airway<br> | Device: Laryngeal mask airway<br>* COMPLETE<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severe respiratory adverse events | laryngospasm, bronchospasm | perioperative period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laryngeal mask airway, Endotracheal intubation, Obese
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
An observational study in evaluating the clinical impact of procalcitonin on the care of Stem cell transplant recipient and its performance as an adjunct in the diagnosis and prognostication of Infectious processes

Detailed Description
-----------------
The overall goal of this project will be to provide new insights into the use of biomarkers in surveillance for infectious processes in Stem Cell Transplant recipients by evaluating the added impact of procalcitonin testing on detection of infectious processes

Official Title
-----------------
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes

Conditions
-----------------
Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age 18-95 years with Multiple Myeloma (MM) undergoing stem cell transplantation Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of Procalcitonin | Levels of Procalcitonin will be measured daily for a period not to exceed 30 days. | Daily up to 30 days |
RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses

Study Overview
=================
Brief Summary
-----------------
The proposed study will investigate the efficacy of the peripheral cutting balloon (PBC) compared to the high pressure balloon in dilating venous stenosis in hemodialysis fistulas. 2. SPECIFIC AIMS Study endpoints will be: Primary Endpoint 1. Primary and assisted patency at 6 months Secondary Endpoints: Procedure effectiveness/residual stenosis Procedure-related complications Primary patency and primary assisted patency 12 months Secondary patency at 6 and 12 months Number/type of secondary interventions.

Official Title
-----------------
A Randomised-Controlled Study Comparing the Peripheral Cutting BalloonTM (Boston Scientific Co.) With a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses

Conditions
-----------------
Stenosis

Intervention / Treatment
-----------------
* Procedure: CUTTING BALLOON ANGIOPLASTY
* Procedure: Balloon angioplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dysfunctional fistulas will be recruited based on the presence of clinical and hemodialysis parameters Exclusion Criteria: Arteriovenous prosthetic grafts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>CUTTING BALLOON ANGIOPLASTY | Procedure: CUTTING BALLOON ANGIOPLASTY<br>* CUTTING BALLOON<br>|
| Placebo Comparator: 2<br>Balloon angioplasty with a high pressure balloon | Procedure: CUTTING BALLOON ANGIOPLASTY<br>* CUTTING BALLOON<br>Procedure: Balloon angioplasty<br>* HIGH PRESSURE BALLOON<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary and assisted patency |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BALLOON ANGIOPLASTY, AUTOGENOUS FISTULA
Evaluation of Atacand® (Candesartan) in Daily Medical Practice

Study Overview
=================
Brief Summary
-----------------
This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.

Official Title
-----------------
A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a patient with arterial hypertension who has been prescribed Atacand according to physician's judgement, irrespective of the inclusion in the study Exclusion Criteria: hypersensitivity to candesartan or any other ingredient of Atacand liver function impairment and/or cholestasis severe renal insufficiency woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic and diastolic blood pressure reduction |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and reasons of treatment discontinuation |  | 12 weeks | 
| Patient treatment satisfaction (using 5-point answering scale) as the measure of the patient's overall tolerance |  | 12 weeks | 
| Physician overall evaluation of the therapy (using 5-point answering scale) |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, blood pressure, Atacand®, candesartan
Treatment Strategy for Low-grade Gliomas

Study Overview
=================
Brief Summary
-----------------
Although the prognosis of patients with low-grade glioma (LGG) is generally good, recurrence seems unavoidable in some patients because of the infiltrative growth of the tumors. How to treat LGGs is still under controversy. The role of radiation therapy and chemotherapy in the treatment of LGG need to be further investigated. The purpose of this study is the following: to investigate the role of early radiation therapy in MRI-determined total resected LGGs; to compare the efficacy of early radiation therapy and that of initial chemotherapy in the LGGs without total resection.

Official Title
-----------------
Treatment Strategy for Low-grade Gliomas

Conditions
-----------------
Astrocytomas, Oligodendrogliomas, Oligoastrocytoma

Intervention / Treatment
-----------------
* Radiation: Radiation therapy
* Drug: Temozolomide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed newly diagnosed low-grade gliomas Karnofsky performance status of 60 or more Exclusion Criteria: Previous history of radiation therapy or chemotherapy for gliomas Pregnant or breast feeding Diagnosis of another malignancy may exclude subject from study Evidence or history of bleeding diathesis Evidence or history of hypersensitivity to temozolomide

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Total resection with early radiation<br>Total resected LGGs treated with early radiation | Radiation: Radiation therapy<br> <br> |
| No Intervention: Total resection without radiation<br>Total resected LGGs treated without radiation | |
| Experimental: Residual LGGs with radiation<br>Residual LGGs treated with early radiation | Radiation: Radiation therapy<br> <br> |
| Experimental: Residual LGGs with chemo<br>Residual LGGS treated with temozolomide | Drug: Temozolomide<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of early radiation therapy in MRI-determined total resected LGGs: evaluated as 5-year progression-free survival. |  | 10 years | 
| Efficacy of early radiation therapy vs. initial chemotherapy with temozolomide in LGGs without total resection: evaluated as 5-year progression-free survival. |  | 10 years |
Long Term Follow-up of Hippocampal DBS for Refractory Epilepsy

Study Overview
=================
Brief Summary
-----------------
Follow up of the patients at Ghent University Hospital treated with hippocampal DBS for refractory epilepsy. Endpoints: Long term evaluation of the effects of hippocampal DBS on seizure frequency and cognition Evaluation of the satisfaction of patients and neurologist regarding the rechargeable DBS battery

Official Title
-----------------
Long Term Follow-up of Patients Treated With Hippocampal Deep Brain Stimulation for Refractory Epilepsy

Conditions
-----------------
Refractory Epilepsy

Intervention / Treatment
-----------------
* Other: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treated with hippocampal DBS for refractory epilepsy at Ghent University Hospital Exclusion Criteria: (none)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Questionnaires<br>Questionnaire for patient Questionnaire for neurologist | Other: Questionnaires<br>* Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seizure frequency per month based on seizure diary | Efficacy measured by reduction in seizure frequency before and after implantation | Every six months (up to 2 years after implantation of rechargeable device) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognition | Cognition measured by neuropsychological testing | Yearly (up to 2 years after implantation of rechargeable device) | 
| Number of device problems | Reporting of device problems including long charging time, bad connection between device and charger, high frequency of charging (> 1 time a day). | Every six months (up to 2 years after implantation of rechargeable device) | 
| Number of adverse events | Reporting of adverse events after implantation | Every six months (up to 2 years after implantation of rechargeable device) |